Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 18/20 | 0.72 |
| ▸ | MERTK | Q12866 | 10/20 | 0.67 |
| ▸ | MET | P08581 | 9/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | HCK | P08631 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22950568 | 1.00 | AXL (0.72) | AXLMERTKMETKDRRET | |
| SCHEMBL30537408 | 0.92 | AXL (0.73) | AXLMERTKMETKDRRET | |
| SCHEMBL22949639 | 0.92 | AXL (0.73) | AXLMERTKMETKDRRET | |
| SCHEMBL22949662 | 0.92 | AXL (0.69) | AXLMERTKMETKDRRET | |
| SCHEMBL30537442 | 0.92 | AXL (0.69) | AXLMERTKMETKDRRET | |
| SCHEMBL22949563 | 0.90 | AXL (0.80) | AXLMERTKMETKDRRET | |
| SCHEMBL30537432 | 0.90 | AXL (0.80) | AXLMERTKMETKDRRET | |
| SCHEMBL21200460 | 0.90 | AXL (0.84) | AXLMERTKMETKDRRET | |
| SCHEMBL30152465 | 0.90 | AXL (0.84) | AXLMERTKMETKDRRET | |
| SCHEMBL28539123 | 0.87 | AXL (0.56) | AXLMERTKMETKDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | AXL 288/4885MERTK 22/4885MET 117/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | AXL 288/4885MERTK 22/4885MET 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.